ClinicalTrials.gg
CompletedNCT04740931COMINOUpdated Aug 6, 2024Results posted

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

A Phase 3 interventional study of Faricimab and Aflibercept in Macular Edema, Central Retinal Vein Occlusion and Hemiretinal Vein Occlusion, sponsored by Hoffmann-La Roche. Completed at 194 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
729
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.

Enrollment
4th of 13
729 · median 229
Started
2021
with 1 other
Phase 3
7 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
8 of 13
Hoffmann-La Roche

Among the 13 studies testing faricimab in Macular Edema, this one is the 4th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 3, and was the 7th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:

About faricimab

faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing faricimab in Macular Edema, or all of them as a file.
02

Study summary

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in patients with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).

03

Conditions studied

  • Macular Edema
  • Central Retinal Vein Occlusion
  • Hemiretinal Vein Occlusion

Keywords

  • CRVO
  • HRVO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Foveal center-involved macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO), diagnosed no longer than 4 months prior to the screening visit
  • Best-corrected visual acuity (BCVA) of 73 to 19 letters, inclusive (20/40 to 20/400 approximate Snellen equivalent)
  • Sufficiently clear ocular media and adequate pupillary dilatation to allow acquisition of good quality retinal images to confirm diagnosis
  • For women of : agreement to remain abstinent or use , and agreement to refrain from donating eggs during the treatment period and for 3 months after the final dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Any major illness or major surgical procedure within 1 month before screening
  • Uncontrolled blood pressure
  • Stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to Day 1
  • Pregnant or breastfeeding, or intending to become pregnant during the study

Ocular Exclusion Criteria for Study Eye:

  • History of previous episodes of macular edema due to RVO or persistent macular edema due to RVO diagnosed more than 4 months before screening
  • Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than macular edema due to RVO in the study eye (e.g., ischemic maculopathy, Irvine-Gass syndrome, foveal atrophy, foveal fibrosis, pigment abnormalities, dense subfoveal hard exudates, or other non-retinal conditions)
  • Macular laser (focal/grid) in the study eye at any time prior to Day 1
  • Panretinal photocoagulation in the study eye within 3 months prior to Day 1 or anticipated within 3 months of study start on Day 1
  • Any prior or current treatment for macular edema; macular neovascularization, including diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); and vitreomacular-interface abnormalities, including, but not restricted to, IVT treatment with anti-VEGF, , tissue plasminogen activator, ocriplasmin, C3F8, air or periocular injection
  • Any prior intervention with verteporfin photodynamic therapy, diode laser, transpupillary thermotherapy, or vitreo-retinal surgery including sheathotomy
  • Any prior steroid implant use including dexamethasone intravitreal implant (Ozurdex) and fluocinolone acetonide intravitreal implant (Iluvien)

Ocular Exclusion Criteria for Both Eyes:

  • Prior IVT administration of faricimab in either eye
  • History of idiopathic or -associated uveitis in either eye
  • Active periocular, ocular or intraocular inflammation or infection (including suspected) in either eye on Day 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
729 participants (actual)

Study arms

  • Experimental
    Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)

    In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm A will receive faricimab 6 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).

    Drug: Faricimab · Procedure: Sham Procedure

  • Active comparator
    Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)

    In Part 1 (Day 1 through Week 24), participants randomly assigned to Arm B will receive aflibercept 2 milligrams (mg) by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections). In Part 2 (from Week 24 to Week 72), participants will receive faricimab 6 mg by IVT injection according to a personalized treatment interval (PTI) dosing regimen. To preserve masking for Part 2, a sham procedure will be administered during study visits at which no faricimab treatment is administered (according to the PTI dosing regimen).

    Drug: Faricimab · Drug: Aflibercept · Procedure: Sham Procedure

Interventions

  • Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.

    Also known as: VABYSMO®, faricimab-svoa, RG7716, RO6867461

  • Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).

    Also known as: Eylea

  • ProcedureSham Procedure

    The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

06

What researchers measure

Primary outcomes

  1. Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 24

Secondary outcomes

  1. Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  2. Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: From Baseline through Week 24

  3. Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  4. Part 1: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  5. Part 1: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  6. Part 1: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  7. Part 1: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  8. Part 1: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  9. Part 1: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  10. Part 1: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  11. Part 1: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  12. Part 1: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  13. Part 1: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the Bruch's membrane (BM) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  14. Part 1: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24

    Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  15. Part 1: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

    Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  16. Part 1: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

    Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  17. Part 1: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

    Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  18. Part 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24

    The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the ANCOVA analysis, the model uses the non-missing change from baseline in BCVA at Weeks 24 as the response variables adjusted for the treatment group, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA score (≥55 and ≤54 letters) and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were not imputed. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline and Week 24

  19. Parts 1 and 2: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  20. Parts 1 and 2: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  21. Parts 1 and 2: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  22. Parts 1 and 2: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  23. Parts 1 and 2: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  24. Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  25. Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  26. Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  27. Parts 1 and 2: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  28. Parts 1 and 2: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  29. Parts 1 and 2: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  30. Parts 1 and 2: Change From Baseline in NEI VFQ-25 Questionnaire Composite Score at Specified Timepoints Through Week 72

    The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the MMRM analysis, the model adjusted for the treatment group, visit, visit-by-treatment group interaction, baseline NEI VFQ-25 Composite Score continuous), baseline BCVA score (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were implicitly imputed. Invalid BCVA values were excluded. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 24, 48, and 72

  31. Parts 1 and 2: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 72

    Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  32. Parts 1 and 2: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 72

    Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  33. Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

    Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  34. Parts 1 and 2: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

    Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  35. Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

    Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  36. Part 2: Change From Week 24 in BCVA in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

    Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  37. Part 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  38. Part 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  39. Part 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  40. Part 2: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

    Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

    Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  41. Part 2: Percentage of Participants on Different Treatment Intervals at Week 68

    In Part 2 of the study, participants in both the faricimab Q4W and aflibercept Q4W arms in Part 1 received 6 mg faricimab intravitreal injections administered according to a personalized treatment interval (PTI) dosing regimen in intervals between Q4W and Q16W. At faricimab dosing visits, treatment intervals were maintained or adjusted (i.e., increased by 4 weeks or decreased by 4, 8, or 12 weeks), based on central subfield thickness (CST) and BCVA values.

    Time frame: Week 68

  42. Part 2: Number of Study Drug Injections Received in the Study Eye From Week 24 Through Week 72

    Time frame: From Week 24 to Week 72

  43. Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale

    This analysis of adverse events (AEs) only includes ocular AEs that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

    Time frame: Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

  44. Incidence of Ocular Adverse Events in the Fellow Eye

    This analysis of adverse events (AEs) only includes ocular AEs that occurred in the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

    Time frame: Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

  45. Incidence of Non-Ocular Adverse Events

    This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

    Time frame: Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72

  46. Plasma Concentration of Faricimab Over Time

    Time frame: Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72

  47. Number of Participants With Anti-Drug Antibodies (ADAs) to Faricimab at Baseline and Post-Baseline During the Study

    Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The number of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period. Treatment-unaffected ADA-positive is a post-baseline sample with a titer that is lower than 4-fold the ADA-positive baseline titer (faricimab arm) or the ADA-positive titer prior to first faricimab injection (aflibercept arm).

    Time frame: Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72

07

Results

Posted Jan 18, 2024

Participant flow

Part 1 (Baseline up to Week 24)
Participant flow — Part 1 (Baseline up to Week 24)
MilestoneArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Started366363
Received at least one dose of study drug365361
Completed360353
Not completed610
Withdrew: Withdrawal by subject04
Withdrew: Death12
Withdrew: Non-compliance with study drug20
Withdrew: Reason not specified20
Withdrew: Adverse event11
Withdrew: Protocol violation01
Withdrew: Physician decision01
Withdrew: Lost to follow-up01
Part 2 (Week 24 to Week 72)
Participant flow — Part 2 (Week 24 to Week 72)
MilestoneArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Started360353
Completed333323
Not completed2730
Withdrew: Withdrawal by subject1111
Withdrew: Lost to follow-up39
Withdrew: Adverse event55
Withdrew: Death41
Withdrew: Other13
Withdrew: Physician decision21
Withdrew: Non-compliance with study drug10

Outcome measures

PrimaryPart 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 24
Reported as:
Mean · ETDRS Letters
Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24
ETDRS LettersArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 2416.9 (15.4 to 18.3)17.3 (15.9 to 18.8)
Statistical analysis
  • Arm A: Faricimab Q4W (Part 1) vs Arm B: Aflibercept Q4W (Part 1) · Difference in adjusted means: -0.4 · 95% CI -2.5 to 1.6The treatment difference in adjusted means of change from baseline BCVA is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
  • Arm A: Faricimab Q4W (Part 1) vs Arm B: Aflibercept Q4W (Part 1) · Mixed Model of Repeated Measures · p = 0.6715 (Tested at a two-sided p\<0.0497 significance level.) · Difference in adjusted means: -0.4 · 95% CI -2.5 to 1.6The treatment difference in adjusted means of change from baseline BCVA is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.
SecondaryPart 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · ETDRS Letters
Part 1: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 24
ETDRS LettersArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 413.5 (12.5 to 14.6)14.3 (13.2 to 15.4)
Week 815.5 (14.4 to 16.7)16.5 (15.3 to 17.7)
Week 1216.9 (15.7 to 18.2)17.1 (15.8 to 18.4)
Week 1616.8 (15.4 to 18.1)17.5 (16.2 to 18.9)
Week 2017.0 (15.6 to 18.3)17.2 (15.8 to 18.5)
Week 2416.9 (15.4 to 18.3)17.3 (15.9 to 18.8)
SecondaryPart 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
From Baseline through Week 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Week 2456.6 (51.7 to 61.5)58.1 (53.3 to 62.9)
Statistical analysis
  • Arm A: Faricimab Q4W (Part 1) vs Arm B: Aflibercept Q4W (Part 1) · Difference in cmh weighted percentage: -1.5 · 95% CI -8.4 to 5.3
SecondaryPart 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 441.5 (36.7 to 46.3)45.4 (40.7 to 50.2)
Week 851.1 (46.3 to 55.9)53.7 (48.9 to 58.5)
Week 1254.6 (49.8 to 59.4)55.1 (50.3 to 59.9)
Week 1657.7 (52.8 to 62.5)59.5 (54.7 to 64.3)
Week 2056.6 (51.7 to 61.4)57.8 (53.0 to 62.6)
Week 2456.6 (51.7 to 61.5)58.1 (53.3 to 62.9)
SecondaryPart 1: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 460.9 (56.0 to 65.8)62.3 (57.6 to 66.9)
Week 869.1 (64.5 to 73.7)72.8 (68.3 to 77.2)
Week 1273.2 (68.8 to 77.7)74.7 (70.3 to 79.0)
Week 1673.5 (69.1 to 78.0)75.8 (71.4 to 80.1)
Week 2072.4 (68.0 to 76.9)74.1 (69.7 to 78.5)
Week 2472.2 (67.7 to 76.6)73.3 (68.8 to 77.7)
SecondaryPart 1: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 483.1 (79.3 to 86.9)83.5 (79.7 to 87.2)
Week 885.2 (81.7 to 88.8)86.8 (83.3 to 90.2)
Week 1287.4 (84.1 to 90.8)87.1 (83.7 to 90.5)
Week 1686.3 (82.9 to 89.8)88.7 (85.5 to 92.0)
Week 2084.1 (80.5 to 87.8)86.5 (83.0 to 90.0)
Week 2485.3 (81.8 to 88.8)84.6 (80.9 to 88.2)
SecondaryPart 1: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 492.1 (89.4 to 94.8)95.6 (93.5 to 97.7)
Week 892.1 (89.4 to 94.8)94.8 (92.5 to 97.0)
Week 1293.2 (90.6 to 95.7)92.6 (89.9 to 95.2)
Week 1692.6 (90.0 to 95.3)92.0 (89.3 to 94.8)
Week 2090.5 (87.5 to 93.4)91.4 (88.6 to 94.3)
Week 2490.5 (87.5 to 93.4)89.2 (86.1 to 92.4)
SecondaryPart 1: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 498.4 (97.1 to 99.7)98.9 (97.8 to 100.0)
Week 898.1 (96.7 to 99.5)98.1 (96.7 to 99.5)
Week 1298.6 (97.5 to 99.8)97.5 (95.9 to 99.1)
Week 1697.3 (95.6 to 98.9)97.0 (95.2 to 98.7)
Week 2097.0 (95.3 to 98.7)96.7 (94.9 to 98.5)
Week 2496.2 (94.3 to 98.1)96.7 (94.9 to 98.5)
SecondaryPart 1: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 498.1 (96.7 to 99.5)98.6 (97.4 to 99.8)
Week 897.5 (96.0 to 99.1)97.5 (95.9 to 99.1)
Week 1297.8 (96.3 to 99.3)97.0 (95.2 to 98.7)
Week 1695.9 (93.9 to 97.9)96.1 (94.2 to 98.1)
Week 2096.7 (94.9 to 98.5)96.1 (94.2 to 98.1)
Week 2495.1 (92.9 to 97.3)95.9 (93.8 to 97.9)
SecondaryPart 1: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 497.0 (95.3 to 98.7)98.1 (96.7 to 99.5)
Week 896.2 (94.2 to 98.1)96.4 (94.5 to 98.3)
Week 1295.9 (93.9 to 97.9)96.1 (94.2 to 98.1)
Week 1695.4 (93.2 to 97.5)94.8 (92.5 to 97.0)
Week 2094.8 (92.6 to 97.1)93.9 (91.5 to 96.4)
Week 2494.0 (91.6 to 96.4)93.7 (91.2 to 96.1)
SecondaryPart 1: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 46.0 (3.6 to 8.4)4.7 (2.6 to 6.8)
Week 88.7 (5.9 to 11.5)10.2 (7.2 to 13.2)
Week 1210.9 (7.8 to 14.0)11.9 (8.7 to 15.0)
Week 1611.5 (8.4 to 14.6)14.1 (10.7 to 17.5)
Week 2014.2 (10.9 to 17.6)14.9 (11.4 to 18.3)
Week 2414.5 (11.0 to 17.9)15.2 (11.7 to 18.7)
SecondaryPart 1: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 445.0 (41.0 to 49.1)46.1 (41.9 to 50.2)
Week 848.6 (44.3 to 52.8)54.6 (50.5 to 58.7)
Week 1254.9 (50.8 to 58.9)55.7 (51.4 to 60.0)
Week 1654.9 (50.6 to 59.1)59.3 (55.2 to 63.4)
Week 2054.1 (49.7 to 58.4)57.6 (53.4 to 61.8)
Week 2455.7 (51.3 to 60.0)59.0 (54.5 to 63.4)
SecondaryPart 1: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 410.0 (7.3 to 12.8)8.6 (6.1 to 11.1)
Week 88.2 (5.5 to 10.8)7.0 (4.6 to 9.4)
Week 127.3 (4.9 to 9.8)6.4 (4.0 to 8.8)
Week 167.8 (5.3 to 10.4)6.2 (3.8 to 8.5)
Week 208.4 (5.7 to 11.0)6.4 (4.0 to 8.8)
Week 2410.1 (7.1 to 13.0)7.5 (4.9 to 10.1)
SecondaryPart 1: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the Bruch's membrane (BM) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · microns
Part 1: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 24
micronsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 4-420.8 (-429.2 to -412.5)-417.3 (-425.6 to -409.0)
Week 8-444.2 (-452.7 to -435.7)-437.5 (-446.1 to -429.0)
Week 12-451.0 (-460.6 to -441.5)-442.5 (-452.1 to -433.0)
Week 16-452.5 (-461.8 to -443.1)-445.2 (-454.7 to -435.8)
Week 20-459.4 (-467.8 to -451.0)-445.1 (-453.6 to -436.6)
Week 24-461.6 (-471.4 to -451.9)-448.8 (-458.6 to -439.0)
SecondaryPart 1: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24

Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 483.8 (80.2 to 87.5)82.4 (78.5 to 86.2)
Week 892.6 (90.0 to 95.2)91.2 (88.3 to 94.1)
Week 1293.4 (90.9 to 95.9)91.5 (88.6 to 94.3)
Week 1694.5 (92.2 to 96.8)92.8 (90.2 to 95.5)
Week 2094.8 (92.6 to 97.1)93.1 (90.5 to 95.7)
Week 2493.7 (91.2 to 96.2)92.0 (89.2 to 94.7)
SecondaryPart 1: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 445.5 (40.6 to 50.5)40.3 (35.6 to 45.0)
Week 863.1 (58.3 to 68.0)61.7 (56.9 to 66.6)
Week 1253.2 (48.3 to 58.2)51.0 (46.2 to 55.9)
Week 1655.4 (50.5 to 60.3)51.9 (46.8 to 56.9)
Week 2059.0 (54.0 to 63.9)56.5 (51.6 to 61.5)
Week 2476.2 (71.9 to 80.5)70.8 (66.2 to 75.4)
SecondaryPart 1: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 466.1 (61.4 to 70.8)65.0 (60.3 to 69.7)
Week 889.6 (86.5 to 92.6)90.1 (87.0 to 93.1)
Week 1294.0 (91.6 to 96.4)93.9 (91.5 to 96.4)
Week 1695.3 (93.2 to 97.5)95.6 (93.5 to 97.7)
Week 2095.9 (93.9 to 97.9)94.5 (92.2 to 96.8)
Week 2496.4 (94.6 to 98.3)93.4 (90.8 to 95.9)
SecondaryPart 1: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24

Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 24
Percentage of participantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Week 433.0 (28.3 to 37.6)29.3 (24.9 to 33.7)
Week 859.3 (54.4 to 64.1)59.3 (54.3 to 64.2)
Week 1252.7 (47.7 to 57.6)50.2 (45.3 to 55.1)
Week 1654.9 (49.9 to 59.8)51.3 (46.3 to 56.3)
Week 2058.2 (53.2 to 63.1)55.4 (50.5 to 60.4)
Week 2475.1 (70.8 to 79.5)68.6 (63.8 to 73.4)
SecondaryPart 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24

The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the ANCOVA analysis, the model uses the non-missing change from baseline in BCVA at Weeks 24 as the response variables adjusted for the treatment group, baseline NEI VFQ-25 Composite Score (continuous), baseline BCVA score (≥55 and ≤54 letters) and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were not imputed. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline and Week 24
Reported as:
Mean · score on a scale
Part 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 24
score on a scaleArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)
Part 1: Change From Baseline in National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25) Composite Score at Week 246.9 (5.8 to 8.0)8.1 (7.0 to 9.2)
Statistical analysis
  • Arm A: Faricimab Q4W (Part 1) vs Arm B: Aflibercept Q4W (Part 1) · Difference in adjusted means: -1.2 · 95% CI -2.7 to 0.3
SecondaryParts 1 and 2: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Mean · ETDRS Letters
Parts 1 and 2: Change From Baseline in BCVA in the Study Eye at Specified Timepoints Through Week 72
ETDRS LettersArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 413.6 (12.5 to 14.6)14.3 (13.3 to 15.4)
Week 815.6 (14.4 to 16.8)16.5 (15.4 to 17.7)
Week 1217.0 (15.7 to 18.2)17.2 (15.9 to 18.4)
Week 1616.8 (15.5 to 18.1)17.6 (16.2 to 18.9)
Week 2017.0 (15.7 to 18.4)17.3 (15.9 to 18.6)
Week 2416.9 (15.5 to 18.3)17.3 (15.9 to 18.8)
Week 2816.0 (14.5 to 17.5)16.0 (14.4 to 17.5)
Week 3217.2 (15.7 to 18.7)17.5 (16.0 to 19.0)
Week 3617.0 (15.5 to 18.5)17.5 (15.9 to 19.0)
Week 4015.8 (14.2 to 17.5)16.2 (14.5 to 17.9)
Week 4416.5 (14.9 to 18.2)17.3 (15.7 to 19.0)
Week 4816.9 (15.2 to 18.5)17.6 (15.9 to 19.3)
Week 5216.4 (14.8 to 18.1)17.8 (16.2 to 19.5)
Week 5616.0 (14.3 to 17.7)16.9 (15.2 to 18.6)
Week 6016.9 (15.2 to 18.6)17.3 (15.6 to 19.0)
Week 6416.8 (15.1 to 18.5)17.2 (15.5 to 18.9)
Week 6816.9 (15.2 to 18.7)17.0 (15.2 to 18.7)
Week 7216.9 (15.1 to 18.6)17.1 (15.3 to 18.8)
SecondaryParts 1 and 2: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants Gaining ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 441.5 (36.7 to 46.3)45.2 (40.4 to 49.9)
Week 851.1 (46.3 to 55.9)53.7 (48.9 to 58.5)
Week 1254.6 (49.8 to 59.4)55.1 (50.3 to 59.9)
Week 1657.7 (52.8 to 62.5)59.5 (54.7 to 64.3)
Week 2056.6 (51.7 to 61.4)57.8 (53.0 to 62.6)
Week 2456.6 (51.7 to 61.5)58.1 (53.3 to 62.9)
Week 2853.3 (48.4 to 58.2)54.8 (50.0 to 59.6)
Week 3260.9 (56.1 to 65.8)57.6 (52.7 to 62.4)
Week 3658.2 (53.3 to 63.1)58.9 (54.2 to 63.7)
Week 4056.6 (51.7 to 61.4)55.9 (51.1 to 60.7)
Week 4455.7 (50.9 to 60.6)57.3 (52.5 to 62.1)
Week 4858.8 (53.9 to 63.6)58.1 (53.3 to 62.9)
Week 5257.6 (52.7 to 62.5)58.7 (53.8 to 63.5)
Week 5656.3 (51.3 to 61.2)57.3 (52.5 to 62.2)
Week 6058.2 (53.3 to 63.1)59.0 (54.1 to 63.8)
Week 6457.1 (52.3 to 61.9)59.5 (54.7 to 64.3)
Week 6856.8 (52.0 to 61.6)59.8 (54.9 to 64.6)
Week 7258.7 (53.9 to 63.6)60.0 (55.2 to 64.9)
SecondaryParts 1 and 2: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants Gaining ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 460.9 (56.0 to 65.8)62.3 (57.6 to 66.9)
Week 869.1 (64.5 to 73.7)72.8 (68.3 to 77.2)
Week 1273.2 (68.8 to 77.7)74.7 (70.3 to 79.0)
Week 1673.5 (69.1 to 78.0)75.8 (71.4 to 80.1)
Week 2072.4 (68.0 to 76.9)74.1 (69.7 to 78.5)
Week 2472.2 (67.7 to 76.6)73.3 (68.8 to 77.7)
Week 2869.7 (65.1 to 74.3)70.5 (66.0 to 75.1)
Week 3273.0 (68.5 to 77.4)74.4 (70.0 to 78.8)
Week 3673.8 (69.3 to 78.2)74.9 (70.6 to 79.3)
Week 4071.0 (66.5 to 75.6)73.0 (68.6 to 77.5)
Week 4471.6 (67.1 to 76.1)74.1 (69.7 to 78.5)
Week 4871.9 (67.3 to 76.4)75.5 (71.1 to 79.9)
Week 5271.0 (66.4 to 75.6)73.8 (69.4 to 78.3)
Week 5670.8 (66.2 to 75.3)72.2 (67.6 to 76.7)
Week 6072.7 (68.2 to 77.2)72.5 (67.9 to 77.0)
Week 6472.4 (67.9 to 76.9)71.6 (67.0 to 76.2)
Week 6872.1 (67.7 to 76.6)70.5 (65.9 to 75.1)
Week 7271.6 (67.1 to 76.1)73.0 (68.5 to 77.5)
SecondaryParts 1 and 2: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants Gaining ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 483.1 (79.3 to 86.9)83.5 (79.7 to 87.2)
Week 885.2 (81.7 to 88.8)86.8 (83.3 to 90.2)
Week 1287.4 (84.1 to 90.8)87.1 (83.7 to 90.5)
Week 1686.3 (82.9 to 89.8)88.7 (85.5 to 92.0)
Week 2084.1 (80.5 to 87.8)86.5 (83.0 to 90.0)
Week 2485.3 (81.8 to 88.8)84.6 (80.9 to 88.2)
Week 2881.7 (77.8 to 85.6)84.0 (80.3 to 87.7)
Week 3284.2 (80.5 to 87.8)87.3 (83.9 to 90.7)
Week 3684.7 (81.1 to 88.3)85.7 (82.1 to 89.3)
Week 4082.3 (78.4 to 86.1)84.3 (80.6 to 88.0)
Week 4482.8 (79.0 to 86.6)84.9 (81.2 to 88.5)
Week 4883.6 (79.9 to 87.3)83.7 (80.0 to 87.5)
Week 5280.9 (76.9 to 84.8)84.0 (80.3 to 87.8)
Week 5679.2 (75.2 to 83.3)81.5 (77.6 to 85.5)
Week 6082.8 (79.0 to 86.6)81.6 (77.6 to 85.5)
Week 6480.6 (76.6 to 84.6)81.5 (77.6 to 85.5)
Week 6883.3 (79.6 to 87.1)80.2 (76.1 to 84.2)
Week 7283.6 (79.9 to 87.3)79.6 (75.5 to 83.7)
SecondaryParts 1 and 2: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants Gaining >0 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 492.1 (89.4 to 94.8)95.6 (93.5 to 97.7)
Week 892.1 (89.4 to 94.8)94.8 (92.5 to 97.0)
Week 1293.2 (90.6 to 95.7)92.6 (89.9 to 95.2)
Week 1692.6 (90.0 to 95.3)92.0 (89.3 to 94.8)
Week 2090.5 (87.5 to 93.4)91.4 (88.6 to 94.3)
Week 2490.5 (87.5 to 93.4)89.2 (86.1 to 92.4)
Week 2888.0 (84.7 to 91.3)88.4 (85.2 to 91.7)
Week 3289.4 (86.2 to 92.5)92.0 (89.2 to 94.8)
Week 3689.9 (86.9 to 93.0)90.1 (87.0 to 93.1)
Week 4087.7 (84.5 to 91.0)88.7 (85.5 to 91.9)
Week 4488.5 (85.3 to 91.7)89.2 (86.1 to 92.4)
Week 4888.5 (85.3 to 91.7)88.7 (85.5 to 91.9)
Week 5285.8 (82.2 to 89.3)89.0 (85.8 to 92.2)
Week 5685.8 (82.3 to 89.3)87.3 (83.9 to 90.7)
Week 6086.6 (83.2 to 90.0)87.3 (83.9 to 90.7)
Week 6486.1 (82.6 to 89.6)86.2 (82.7 to 89.7)
Week 6887.4 (84.1 to 90.8)85.4 (81.8 to 89.0)
Week 7286.6 (83.2 to 90.1)85.7 (82.1 to 89.2)
SecondaryParts 1 and 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 498.4 (97.1 to 99.7)98.9 (97.8 to 100.0)
Week 898.1 (96.7 to 99.5)98.1 (96.7 to 99.5)
Week 1298.6 (97.5 to 99.8)97.5 (95.9 to 99.1)
Week 1697.3 (95.6 to 98.9)97.0 (95.2 to 98.7)
Week 2097.0 (95.3 to 98.7)96.7 (94.9 to 98.5)
Week 2496.2 (94.3 to 98.1)96.7 (94.9 to 98.5)
Week 2895.6 (93.6 to 97.7)94.2 (91.8 to 96.6)
Week 3295.4 (93.3 to 97.5)96.1 (94.2 to 98.1)
Week 3695.4 (93.3 to 97.5)95.9 (93.8 to 97.9)
Week 4094.0 (91.6 to 96.4)95.9 (93.8 to 97.9)
Week 4494.0 (91.6 to 96.4)95.6 (93.5 to 97.7)
Week 4894.0 (91.6 to 96.4)95.6 (93.5 to 97.7)
Week 5294.6 (92.3 to 96.8)96.7 (94.9 to 98.5)
Week 5695.1 (92.9 to 97.3)95.6 (93.5 to 97.7)
Week 6093.5 (91.0 to 96.0)95.3 (93.2 to 97.5)
Week 6494.0 (91.6 to 96.4)94.8 (92.5 to 97.0)
Week 6893.5 (90.9 to 96.0)95.9 (93.8 to 97.9)
Week 7293.2 (90.6 to 95.7)95.0 (92.8 to 97.2)
SecondaryParts 1 and 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 498.1 (96.7 to 99.5)98.6 (97.4 to 99.8)
Week 897.5 (96.0 to 99.1)97.5 (95.9 to 99.1)
Week 1297.8 (96.3 to 99.3)97.0 (95.2 to 98.7)
Week 1695.9 (93.9 to 97.9)96.1 (94.2 to 98.1)
Week 2096.7 (94.9 to 98.5)96.1 (94.2 to 98.1)
Week 2495.1 (92.9 to 97.3)95.9 (93.8 to 97.9)
Week 2894.6 (92.3 to 96.9)93.4 (90.9 to 95.9)
Week 3294.3 (91.9 to 96.6)95.9 (93.8 to 97.9)
Week 3694.3 (91.9 to 96.6)95.0 (92.8 to 97.3)
Week 4092.9 (90.3 to 95.5)93.9 (91.5 to 96.4)
Week 4493.2 (90.7 to 95.7)94.5 (92.2 to 96.8)
Week 4892.4 (89.7 to 95.0)93.9 (91.5 to 96.4)
Week 5292.9 (90.3 to 95.5)95.0 (92.8 to 97.2)
Week 5691.3 (88.4 to 94.1)93.6 (91.2 to 96.1)
Week 6092.1 (89.4 to 94.8)94.5 (92.2 to 96.8)
Week 6492.9 (90.3 to 95.5)93.9 (91.5 to 96.4)
Week 6892.6 (90.0 to 95.3)94.2 (91.8 to 96.6)
Week 7292.6 (90.0 to 95.3)93.7 (91.2 to 96.1)
SecondaryParts 1 and 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Baseline in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 497.0 (95.3 to 98.7)98.1 (96.7 to 99.5)
Week 896.2 (94.2 to 98.1)96.4 (94.5 to 98.3)
Week 1295.9 (93.9 to 97.9)96.1 (94.2 to 98.1)
Week 1695.4 (93.2 to 97.5)94.8 (92.5 to 97.0)
Week 2094.8 (92.6 to 97.1)93.9 (91.5 to 96.4)
Week 2494.0 (91.6 to 96.4)93.7 (91.2 to 96.1)
Week 2892.4 (89.7 to 95.1)91.7 (88.9 to 94.5)
Week 3291.3 (88.4 to 94.1)94.8 (92.5 to 97.0)
Week 3692.7 (90.0 to 95.3)94.2 (91.8 to 96.6)
Week 4091.0 (88.1 to 93.9)92.6 (89.9 to 95.2)
Week 4490.7 (87.8 to 93.6)92.8 (90.2 to 95.4)
Week 4891.0 (88.1 to 93.9)92.6 (89.9 to 95.2)
Week 5290.5 (87.5 to 93.4)93.4 (90.9 to 95.9)
Week 5688.5 (85.3 to 91.7)91.4 (88.6 to 94.3)
Week 6090.5 (87.5 to 93.4)92.3 (89.6 to 95.0)
Week 6490.7 (87.8 to 93.7)91.2 (88.3 to 94.1)
Week 6889.6 (86.6 to 92.7)91.7 (88.9 to 94.5)
Week 7290.5 (87.5 to 93.4)90.6 (87.7 to 93.6)
SecondaryParts 1 and 2: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants Achieving ≥84 Letters in BCVA (20/20 Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 46.0 (3.6 to 8.4)4.7 (2.6 to 6.8)
Week 88.7 (5.9 to 11.5)10.2 (7.2 to 13.2)
Week 1210.9 (7.8 to 14.0)11.9 (8.7 to 15.0)
Week 1611.5 (8.4 to 14.6)14.1 (10.7 to 17.5)
Week 2014.2 (10.9 to 17.6)14.9 (11.4 to 18.3)
Week 2414.5 (11.0 to 17.9)15.2 (11.7 to 18.7)
Week 289.8 (6.9 to 12.8)12.7 (9.5 to 15.9)
Week 3213.4 (10.0 to 16.7)14.9 (11.4 to 18.3)
Week 3615.3 (11.8 to 18.8)14.9 (11.5 to 18.3)
Week 4014.8 (11.3 to 18.2)12.4 (9.2 to 15.7)
Week 4415.5 (12.0 to 19.1)14.1 (10.7 to 17.5)
Week 4815.0 (11.6 to 18.5)14.6 (11.2 to 18.0)
Week 5216.7 (13.0 to 20.3)14.9 (11.4 to 18.4)
Week 5614.8 (11.3 to 18.2)15.5 (12.0 to 18.9)
Week 6015.8 (12.3 to 19.4)16.3 (12.7 to 19.9)
Week 6416.1 (12.5 to 19.8)15.7 (12.2 to 19.3)
Week 6815.3 (11.8 to 18.9)15.2 (11.7 to 18.7)
Week 7215.3 (11.8 to 18.8)14.4 (11.0 to 17.7)
SecondaryParts 1 and 2: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants Achieving ≥69 Letters in BCVA (20/40 or Better Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 445.0 (41.0 to 49.1)46.1 (41.9 to 50.2)
Week 848.6 (44.3 to 52.8)54.6 (50.5 to 58.7)
Week 1254.9 (50.8 to 58.9)55.7 (51.4 to 60.0)
Week 1654.9 (50.6 to 59.1)59.3 (55.2 to 63.4)
Week 2054.1 (49.7 to 58.4)57.6 (53.4 to 61.8)
Week 2455.7 (51.3 to 60.0)59.0 (54.5 to 63.4)
Week 2853.2 (48.8 to 57.7)56.2 (51.8 to 60.7)
Week 3256.0 (51.6 to 60.4)60.4 (56.1 to 64.6)
Week 3653.8 (49.4 to 58.2)60.7 (56.3 to 65.0)
Week 4051.9 (47.3 to 56.4)56.2 (51.7 to 60.8)
Week 4453.0 (48.4 to 57.6)60.9 (56.5 to 65.3)
Week 4856.2 (51.8 to 60.7)60.6 (56.2 to 65.1)
Week 5254.3 (49.8 to 58.9)60.4 (55.9 to 64.8)
Week 5651.9 (47.3 to 56.4)58.7 (54.3 to 63.2)
Week 6056.0 (51.5 to 60.4)58.7 (54.3 to 63.1)
Week 6456.5 (52.1 to 61.0)57.9 (53.4 to 62.4)
Week 6856.0 (51.5 to 60.4)57.9 (53.4 to 62.4)
Week 7256.2 (51.7 to 60.8)58.5 (53.9 to 63.1)
SecondaryParts 1 and 2: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (\>38 and ≤38 letters) and region (U.S. and Canada, Asia, and rest of the world). All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants With ≤38 Letters in BCVA (20/200 or Worse Snellen Equivalent) in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 410.0 (7.3 to 12.8)8.6 (6.1 to 11.1)
Week 88.2 (5.5 to 10.8)7.0 (4.6 to 9.4)
Week 127.3 (4.9 to 9.8)6.4 (4.0 to 8.8)
Week 167.8 (5.3 to 10.4)6.2 (3.8 to 8.5)
Week 208.4 (5.7 to 11.0)6.4 (4.0 to 8.8)
Week 2410.1 (7.1 to 13.0)7.5 (4.9 to 10.1)
Week 288.9 (6.1 to 11.7)9.4 (6.6 to 12.3)
Week 329.2 (6.4 to 12.0)8.0 (5.4 to 10.7)
Week 369.5 (6.6 to 12.4)8.3 (5.7 to 11.0)
Week 409.8 (6.8 to 12.7)7.5 (4.9 to 10.1)
Week 4410.6 (7.5 to 13.6)8.3 (5.6 to 11.0)
Week 4810.0 (7.1 to 13.0)7.5 (4.9 to 10.1)
Week 5211.4 (8.3 to 14.5)7.2 (4.7 to 9.8)
Week 5611.9 (8.8 to 15.1)8.6 (5.8 to 11.4)
Week 6011.4 (8.3 to 14.5)8.3 (5.7 to 11.0)
Week 6411.1 (8.0 to 14.2)8.3 (5.6 to 11.0)
Week 6811.2 (8.0 to 14.3)8.3 (5.6 to 11.0)
Week 7211.4 (8.3 to 14.6)8.0 (5.4 to 10.7)
SecondaryParts 1 and 2: Change From Baseline in NEI VFQ-25 Questionnaire Composite Score at Specified Timepoints Through Week 72

The NEI VFQ-25 captures a patient's perception of vision-related functioning and vision-related quality of life. The core measure includes 25 items that comprise 11 vision-related subscales and 1 item on general health. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. For the MMRM analysis, the model adjusted for the treatment group, visit, visit-by-treatment group interaction, baseline NEI VFQ-25 Composite Score continuous), baseline BCVA score (≥55 and ≤54 letters), and region (U.S. and Canada, Asia, and the rest of the world). Observed NEI VFQ-25 assessments were used regardless of the occurrence of intercurrent events. Missing data were implicitly imputed. Invalid BCVA values were excluded. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 24, 48, and 72
Reported as:
Mean · score on a scale
Parts 1 and 2: Change From Baseline in NEI VFQ-25 Questionnaire Composite Score at Specified Timepoints Through Week 72
score on a scaleArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 247.0 (5.9 to 8.0)8.2 (7.1 to 9.3)
Week 487.0 (5.9 to 8.2)8.3 (7.1 to 9.5)
Week 727.8 (6.5 to 9.0)8.5 (7.3 to 9.8)
SecondaryParts 1 and 2: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 72

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline CST (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Mean · microns
Parts 1 and 2: Change From Baseline in Central Subfield Thickness in the Study Eye at Specified Timepoints Through Week 72
micronsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 4-422.1 (-430.6 to -413.7)-418.2 (-426.6 to -409.7)
Week 8-445.1 (-453.6 to -436.6)-438.5 (-447.0 to -429.9)
Week 12-452.3 (-461.8 to -442.8)-443.7 (-453.2 to -434.1)
Week 16-453.8 (-463.1 to -444.5)-446.2 (-455.5 to -436.9)
Week 20-460.0 (-468.1 to -451.8)-447.1 (-455.4 to -438.9)
Week 24-462.3 (-472.3 to -452.3)-447.8 (-457.9 to -437.8)
Week 28-415.5 (-431.8 to -399.1)-413.7 (-430.3 to -397.2)
Week 32-459.4 (-468.7 to -450.1)-445.8 (-455.3 to -436.3)
Week 36-451.7 (-462.7 to -440.8)-441.8 (-452.9 to -430.8)
Week 40-409.8 (-425.6 to -394.0)-414.0 (-429.9 to -398.0)
Week 44-456.6 (-467.1 to -446.0)-449.8 (-460.6 to -439.0)
Week 48-461.2 (-471.3 to -451.1)-448.0 (-458.3 to -437.7)
Week 52-446.0 (-457.0 to -435.0)-451.8 (-462.9 to -440.7)
Week 56-435.9 (-449.8 to -422.0)-426.2 (-440.3 to -412.1)
Week 60-468.2 (-476.8 to -459.5)-458.9 (-467.6 to -450.1)
Week 64-466.6 (-473.7 to -459.5)-465.5 (-472.6 to -458.3)
Week 68-467.5 (-476.0 to -459.1)-457.7 (-466.2 to -449.2)
Week 72-463.5 (-472.8 to -454.3)-458.6 (-467.9 to -449.2)
SecondaryParts 1 and 2: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 72

Absence of diabetic macular edema was defined as achieving a central subfield thickness of \<325 microns in the study eye. Central subfield thickness was defined as the distance between the internal limiting membrane (ILM) and Bruch's membrane (BM) as assessed by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants With Absence of Macular Edema in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 483.8 (80.2 to 87.5)82.4 (78.5 to 86.2)
Week 892.6 (90.0 to 95.2)91.2 (88.3 to 94.1)
Week 1293.4 (90.9 to 95.9)91.5 (88.6 to 94.3)
Week 1694.5 (92.2 to 96.8)92.8 (90.2 to 95.5)
Week 2094.5 (92.2 to 96.8)93.1 (90.5 to 95.7)
Week 2493.7 (91.2 to 96.2)91.7 (88.9 to 94.5)
Week 2882.5 (78.6 to 86.4)84.0 (80.3 to 87.7)
Week 3293.2 (90.6 to 95.7)90.3 (87.4 to 93.3)
Week 3691.8 (89.0 to 94.6)89.5 (86.4 to 92.6)
Week 4080.0 (76.0 to 84.1)80.7 (76.7 to 84.7)
Week 4493.2 (90.6 to 95.7)90.9 (88.0 to 93.8)
Week 4892.6 (89.9 to 95.3)89.8 (86.7 to 92.9)
Week 5288.5 (85.2 to 91.8)90.9 (88.0 to 93.8)
Week 5687.4 (84.1 to 90.8)84.3 (80.6 to 88.0)
Week 6093.7 (91.3 to 96.2)92.8 (90.2 to 95.5)
Week 6494.3 (91.9 to 96.6)93.4 (90.8 to 95.9)
Week 6893.2 (90.6 to 95.7)91.4 (88.6 to 94.3)
Week 7292.4 (89.6 to 95.1)91.2 (88.3 to 94.0)
SecondaryParts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

Intraretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 445.5 (40.6 to 50.5)40.6 (35.8 to 45.3)
Week 863.1 (58.3 to 68.0)61.7 (56.9 to 66.6)
Week 1253.2 (48.3 to 58.2)51.0 (46.2 to 55.9)
Week 1655.4 (50.5 to 60.3)51.9 (46.8 to 56.9)
Week 2059.0 (54.0 to 63.9)56.5 (51.6 to 61.5)
Week 2477.0 (72.8 to 81.3)70.8 (66.2 to 75.4)
Week 2853.8 (48.7 to 58.9)51.5 (46.4 to 56.6)
Week 3267.7 (63.1 to 72.4)67.2 (62.5 to 72.0)
Week 3662.8 (58.1 to 67.5)57.6 (52.6 to 62.6)
Week 4052.7 (47.7 to 57.7)51.0 (46.0 to 56.1)
Week 4466.4 (61.6 to 71.2)63.4 (58.5 to 68.3)
Week 4874.3 (69.9 to 78.8)69.7 (65.0 to 74.3)
Week 5266.9 (62.2 to 71.6)63.4 (58.5 to 68.2)
Week 5660.9 (56.0 to 65.9)58.7 (53.7 to 63.6)
Week 6071.6 (67.0 to 76.1)72.7 (68.2 to 77.2)
Week 6476.5 (72.2 to 80.8)72.7 (68.2 to 77.2)
Week 6874.6 (70.2 to 79.0)71.3 (66.8 to 75.9)
Week 7278.1 (73.9 to 82.3)74.4 (69.9 to 78.9)
SecondaryParts 1 and 2: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

Subretinal fluid was measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants With Absence of Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 466.1 (61.4 to 70.8)65.0 (60.3 to 69.7)
Week 889.6 (86.5 to 92.6)90.1 (87.0 to 93.1)
Week 1294.0 (91.6 to 96.4)93.9 (91.5 to 96.4)
Week 1695.3 (93.2 to 97.5)95.6 (93.5 to 97.7)
Week 2095.9 (93.9 to 97.9)94.5 (92.2 to 96.8)
Week 2496.2 (94.2 to 98.1)93.4 (90.8 to 95.9)
Week 2889.3 (86.2 to 92.5)90.1 (87.0 to 93.1)
Week 3295.6 (93.6 to 97.7)94.5 (92.2 to 96.8)
Week 3695.1 (92.9 to 97.3)92.3 (89.6 to 95.0)
Week 4089.6 (86.5 to 92.7)89.3 (86.1 to 92.4)
Week 4495.4 (93.2 to 97.5)92.8 (90.2 to 95.5)
Week 4893.4 (90.9 to 95.9)89.5 (86.4 to 92.6)
Week 5292.6 (89.9 to 95.3)93.6 (91.2 to 96.1)
Week 5693.4 (90.9 to 95.9)90.1 (87.1 to 93.1)
Week 6097.0 (95.3 to 98.7)94.8 (92.5 to 97.0)
Week 6496.7 (94.9 to 98.5)95.9 (93.8 to 97.9)
Week 6897.6 (96.0 to 99.1)93.9 (91.6 to 96.3)
Week 7295.4 (93.2 to 97.5)93.1 (90.6 to 95.7)
SecondaryParts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72

Intraretinal fluid and subretinal fluid were measured in the study eye using optical coherence tomography (OCT) in the central subfield (center 1 mm) by a central reading center. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Parts 1 and 2: Percentage of Participants With Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Week 433.0 (28.3 to 37.6)29.3 (24.9 to 33.7)
Week 859.3 (54.4 to 64.1)59.3 (54.3 to 64.2)
Week 1252.7 (47.7 to 57.6)50.2 (45.3 to 55.1)
Week 1654.9 (49.9 to 59.8)51.3 (46.3 to 56.3)
Week 2058.2 (53.2 to 63.1)55.4 (50.5 to 60.4)
Week 2476.0 (71.6 to 80.3)68.6 (63.8 to 73.4)
Week 2852.7 (47.6 to 57.8)51.2 (46.1 to 56.3)
Week 3267.2 (62.6 to 71.8)66.4 (61.6 to 71.2)
Week 3662.8 (58.1 to 67.5)56.5 (51.5 to 61.5)
Week 4052.7 (47.7 to 57.7)50.2 (45.1 to 55.2)
Week 4464.7 (59.9 to 69.6)60.9 (56.0 to 65.8)
Week 4870.8 (66.1 to 75.4)65.8 (61.0 to 70.6)
Week 5265.8 (61.1 to 70.6)61.7 (56.8 to 66.6)
Week 5660.7 (55.7 to 65.6)58.1 (53.2 to 63.0)
Week 6071.0 (66.4 to 75.6)71.6 (67.0 to 76.2)
Week 6475.4 (71.1 to 79.8)71.9 (67.3 to 76.4)
Week 6874.3 (69.9 to 78.8)70.8 (66.2 to 75.3)
Week 7277.0 (72.8 to 81.3)71.6 (67.0 to 76.3)
SecondaryPart 2: Change From Week 24 in BCVA in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis included the categorical covariates of treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), and randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\] as fixed effects. An unstructured covariance structure was used. Missing data were implicitly imputed by MMRM model assuming missing at random. Treatment policy strategy (i.e., all observed values used) was applied to all intercurrent events (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). 95% CI is a rounding of 95.03% CI.

Time frame:
Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Mean · ETDRS Letters
Part 2: Change From Week 24 in BCVA in the Study Eye at Specified Timepoints Through Week 72
ETDRS LettersArm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Week 28-0.8 (-1.6 to 0.0)-1.2 (-2.0 to -0.4)
Week 320.2 (-0.6 to 0.9)0.2 (-0.6 to 1.0)
Week 36-0.1 (-0.8 to 0.7)0.1 (-0.7 to 0.9)
Week 40-1.3 (-2.4 to -0.2)-1.4 (-2.4 to -0.3)
Week 44-0.6 (-1.6 to 0.4)0.0 (-1.0 to 1.0)
Week 48-0.1 (-1.1 to 0.9)0.2 (-0.8 to 1.1)
Week 52-0.6 (-1.6 to 0.4)0.3 (-0.6 to 1.3)
Week 56-1.1 (-2.1 to 0.0)-0.6 (-1.7 to 0.5)
Week 600.0 (-1.1 to 1.0)-0.1 (-1.2 to 0.9)
Week 64-0.2 (-1.3 to 0.8)-0.2 (-1.3 to 0.9)
Week 68-0.1 (-1.2 to 1.0)-0.5 (-1.6 to 0.6)
Week 72-0.2 (-1.3 to 1.0)-0.3 (-1.5 to 0.8)
SecondaryPart 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Part 2: Percentage of Participants Avoiding a Loss of ≥15 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Week 2886.3 (82.9 to 89.8)83.8 (80.0 to 87.5)
Week 3288.8 (85.6 to 92.0)87.9 (84.6 to 91.2)
Week 3689.3 (86.2 to 92.5)87.9 (84.6 to 91.2)
Week 4087.4 (84.0 to 90.8)86.0 (82.4 to 89.5)
Week 4487.4 (84.0 to 90.8)88.4 (85.2 to 91.7)
Week 4888.5 (85.3 to 91.7)87.3 (83.9 to 90.7)
Week 5286.3 (82.8 to 89.8)87.6 (84.2 to 91.0)
Week 5685.7 (82.2 to 89.3)85.4 (81.8 to 89.0)
Week 6087.7 (84.3 to 91.0)86.2 (82.7 to 89.8)
Week 6486.3 (82.8 to 89.8)85.9 (82.4 to 89.5)
Week 6887.1 (83.7 to 90.5)85.4 (81.8 to 89.0)
Week 7286.6 (83.1 to 90.0)84.0 (80.3 to 87.8)
SecondaryPart 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Part 2: Percentage of Participants Avoiding a Loss of ≥10 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Week 2882.8 (79.0 to 86.6)81.3 (77.3 to 85.2)
Week 3287.1 (83.7 to 90.6)86.0 (82.4 to 89.5)
Week 3684.7 (81.0 to 88.4)85.4 (81.8 to 89.0)
Week 4082.8 (78.9 to 86.6)81.6 (77.6 to 85.5)
Week 4484.1 (80.4 to 87.9)86.8 (83.4 to 90.2)
Week 4884.4 (80.7 to 88.1)84.8 (81.2 to 88.5)
Week 5282.8 (78.9 to 86.6)85.4 (81.8 to 89.0)
Week 5680.0 (76.0 to 84.1)81.8 (77.9 to 85.8)
Week 6083.6 (79.8 to 87.4)82.6 (78.8 to 86.5)
Week 6481.7 (77.7 to 85.6)83.2 (79.4 to 87.0)
Week 6882.2 (78.3 to 86.1)80.7 (76.7 to 84.7)
Week 7282.5 (78.6 to 86.3)80.7 (76.7 to 84.7)
SecondaryPart 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Part 2: Percentage of Participants Avoiding a Loss of ≥5 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Week 2872.7 (68.2 to 77.2)69.7 (65.0 to 74.4)
Week 3278.4 (74.2 to 82.6)75.5 (71.1 to 79.9)
Week 3674.1 (69.6 to 78.5)80.2 (76.1 to 84.2)
Week 4071.0 (66.4 to 75.6)71.6 (67.0 to 76.2)
Week 4473.7 (69.3 to 78.2)73.0 (68.5 to 77.6)
Week 4876.5 (72.2 to 80.8)74.1 (69.6 to 78.6)
Week 5271.3 (66.7 to 75.9)74.1 (69.6 to 78.6)
Week 5669.4 (64.7 to 74.1)68.3 (63.6 to 73.1)
Week 6074.3 (69.8 to 78.7)71.6 (67.0 to 76.2)
Week 6474.6 (70.1 to 79.0)71.6 (67.0 to 76.2)
Week 6873.2 (68.7 to 77.7)69.2 (64.5 to 73.8)
Week 7272.9 (68.4 to 77.5)70.3 (65.6 to 74.9)
SecondaryPart 2: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The weighted percentage of participants was estimated based on the Cochran-Mantel Haenszel (CMH) weights stratified by randomization stratification factors \[baseline BCVA (≤34, 35-54, and ≥55 letters), and region (U.S. and Canada, Asia, and rest of the world)\]. All observed values were used regardless of the occurrence of an intercurrent event (discontinuation of treatment due to AEs or lack of efficacy, use of prohibited therapy). Missing assessments were imputed by last observation carried forward. 95% CI is a rounding of 95.03% CI.

Time frame:
Weeks 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · Percentage of participants
Part 2: Percentage of Participants Avoiding a Loss of >0 Letters in BCVA From Week 24 in the Study Eye at Specified Timepoints Through Week 72
Percentage of participantsArm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Week 2848.9 (43.8 to 54.0)45.4 (40.4 to 50.5)
Week 3256.0 (50.9 to 61.1)52.9 (47.8 to 58.0)
Week 3655.5 (50.4 to 60.5)55.1 (50.0 to 60.2)
Week 4053.0 (47.9 to 58.0)48.2 (43.1 to 53.3)
Week 4453.0 (47.9 to 58.0)54.0 (49.0 to 59.1)
Week 4856.5 (51.5 to 61.6)53.5 (48.4 to 58.6)
Week 5256.0 (50.9 to 61.1)56.5 (51.4 to 61.5)
Week 5654.9 (49.8 to 60.0)53.2 (48.1 to 58.2)
Week 6055.9 (50.9 to 61.0)51.0 (45.9 to 56.1)
Week 6454.6 (49.5 to 59.7)52.1 (47.0 to 57.2)
Week 6855.4 (50.4 to 60.4)52.3 (47.3 to 57.4)
Week 7255.4 (50.4 to 60.5)52.7 (47.6 to 57.7)
SecondaryPart 2: Percentage of Participants on Different Treatment Intervals at Week 68

In Part 2 of the study, participants in both the faricimab Q4W and aflibercept Q4W arms in Part 1 received 6 mg faricimab intravitreal injections administered according to a personalized treatment interval (PTI) dosing regimen in intervals between Q4W and Q16W. At faricimab dosing visits, treatment intervals were maintained or adjusted (i.e., increased by 4 weeks or decreased by 4, 8, or 12 weeks), based on central subfield thickness (CST) and BCVA values.

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Part 2: Percentage of Participants on Different Treatment Intervals at Week 68
Percentage of participantsArm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Once Every 4 Weeks (Q4W)34.5 (29.4 to 39.7)32.4 (27.2 to 37.6)
Once Every 8 Weeks (Q8W)20.0 (15.7 to 24.3)17.5 (13.3 to 21.7)
Once Every 12 Weeks (Q12W)8.5 (5.5 to 11.5)11.1 (7.6 to 14.6)
Once Every 16 Weeks (Q16W)37.0 (31.8 to 42.2)39.0 (33.7 to 44.4)
SecondaryPart 2: Number of Study Drug Injections Received in the Study Eye From Week 24 Through Week 72
Time frame:
From Week 24 to Week 72
Reported as:
Median · Injections
Part 2: Number of Study Drug Injections Received in the Study Eye From Week 24 Through Week 72
InjectionsArm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Part 2: Number of Study Drug Injections Received in the Study Eye From Week 24 Through Week 725.0 (1 to 12)4.0 (1 to 12)
SecondaryIncidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale

This analysis of adverse events (AEs) only includes ocular AEs that occurred in the study eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

Time frame:
Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72
Reported as:
Count of participants · Participants
Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading Scale
ParticipantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)Arm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Adverse Event (AE)8998130118
AE by Severity: Mild65656369
AE by Severity: Moderate18275243
AE by Severity: Severe66156
Serious Adverse Event (SAE)9132612
AE Leading to Withdrawal from Study Treatment3253
Treatment Related AEs1561411
Treatment Related SAEs3240
Any AE of Special Interest (AESI)812219
AESI: Drop in Visual Acuity Score ≥3066157
AESI: Associated with Severe IOI0001
AESI: Intervention Req. to Prevent Permanent Vision Loss2661
SecondaryIncidence of Ocular Adverse Events in the Fellow Eye

This analysis of adverse events (AEs) only includes ocular AEs that occurred in the fellow eye. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

Time frame:
Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72
Reported as:
Count of participants · Participants
Incidence of Ocular Adverse Events in the Fellow Eye
ParticipantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)Arm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Adverse Event (AE)31337051
Serious Adverse Event (SAE)1110
Any AE of Special Interest (AESI)1110
AESI: Drop in Visual Acuity Score ≥301110
SecondaryIncidence of Non-Ocular Adverse Events

This analysis of adverse events (AEs) only includes non-ocular (systemic) AEs. Investigators sought information on adverse events (AEs) at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

Time frame:
Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72
Reported as:
Count of participants · Participants
Incidence of Non-Ocular Adverse Events
ParticipantsArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)Arm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Adverse Event (AE)123134191174
Serious Adverse Event (SAE)22233041
AE Leading to Withdrawal from Study Treatment0133
Any AE of Special Interest (AESI)0000
SecondaryPlasma Concentration of Faricimab Over Time
Time frame:
Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72
Reported as:
Mean · microgram per millilitre (μg/mL)
Plasma Concentration of Faricimab Over Time
microgram per millilitre (μg/mL)Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)
Baseline0.0001 ± 0.0009—
Week 40.0222 ± 0.0176—
Week 240.0257 ± 0.02170.0005 ± 0.0014
Week 280.0055 ± 0.00860.0026 ± 0.0084
Week 520.0089 ± 0.01420.0090 ± 0.0136
Week 720.0087 ± 0.01400.0099 ± 0.0167
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) to Faricimab at Baseline and Post-Baseline During the Study

Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The number of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period. Treatment-unaffected ADA-positive is a post-baseline sample with a titer that is lower than 4-fold the ADA-positive baseline titer (faricimab arm) or the ADA-positive titer prior to first faricimab injection (aflibercept arm).

Time frame:
Predose at Day 1 (Baseline), Weeks 4, 24, 28, 52, and 72
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADAs) to Faricimab at Baseline and Post-Baseline During the Study
ParticipantsArm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)All Faricimab Participants
Baseline (BL): Total ADA-Positive459
Post-BL: Total ADA-Positive622789
Post-BL: Treatment-Emergent ADA-Positive602383
Post-BL: Treatment-Unaffected ADA-Positive246

Adverse events

Collected over Part 1: From first dose up to Week 24; Part 2: from Week 24 through Week 72. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Faricimab Q4W (Part 1)1/365 (0.3%)32/365 (8.8%)67/365 (18.4%)
Arm B: Aflibercept Q4W (Part 1)2/361 (0.6%)34/361 (9.4%)66/361 (18.3%)
Arm A: Faricimab Q4W to Faricimab PTI (Part 2)4/359 (1.1%)55/359 (15.3%)109/359 (30.4%)
Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)1/342 (0.3%)51/342 (14.9%)118/342 (34.5%)
Most frequent serious events
Showing 10 of 164
Most frequent serious events
EventArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)Arm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
Cystoid macular oedemaEye disorders2/3652/3615/3591/342
Retinal vein occlusionEye disorders2/3652/3615/3593/342
Macular oedemaEye disorders0/3651/3614/3590/342
Myocardial infarctionCardiac disorders0/3653/3613/3590/342
PneumoniaInfections and infestations2/3651/3613/3592/342
COVID-19Infections and infestations3/3650/3611/3590/342
Acute myocardial infarctionCardiac disorders1/3651/3610/3592/342
Retinal artery occlusionEye disorders2/3651/3610/3592/342
SepsisInfections and infestations1/3650/3610/3592/342
Atrial fibrillationCardiac disorders0/3650/3612/3592/342
Most frequent other events
Most frequent other events
EventArm A: Faricimab Q4W (Part 1)Arm B: Aflibercept Q4W (Part 1)Arm A: Faricimab Q4W to Faricimab PTI (Part 2)Arm B: Aflibercept Q4W to Faricimab PTI (Part 2)
COVID-19Infections and infestations14/36512/36142/35946/342
NasopharyngitisInfections and infestations5/3657/36110/35916/342
Intraocular pressure increasedInvestigations9/36512/36116/35915/342
HypertensionVascular disorders15/36510/36112/3598/342
Vitreous detachmentEye disorders11/3659/3616/35914/342
CataractEye disorders3/3657/36114/35914/342
Macular oedemaEye disorders2/3650/3617/35914/342
Conjunctival haemorrhageEye disorders10/36514/36110/3597/342
Epiretinal membraneEye disorders3/3652/3613/35911/342
Cystoid macular oedemaEye disorders1/3653/36111/35910/342

Baseline characteristics

ITT Population: All global participants who were randomized in the study, according to the assigned treatment.

Age, Continuous
Age, Continuous(Years)Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)Total
Mean65.6 ± 13.164.7 ± 13.365.1 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)Total
Female173163336
Male193200393
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)Total
Hispanic or Latino6673139
Not Hispanic or Latino286283569
Unknown or Not Reported14721
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)Total
American Indian or Alaska Native235
Asian8988177
Native Hawaiian or Other Pacific Islander011
Black or African American101323
White243253496
More than one race101
Unknown or Not Reported21526
Region of Enrollment
Region of Enrollment(Participants)Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)Total
Rest of World187187374
USA and Canada9593188
Asia8483167
Number of Participants by the Eye (Left or Right) Chosen as the Study Eye
Number of Participants by the Eye (Left or Right) Chosen as the Study Eye(Participants)Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)Total
Left Eye180181361
Right Eye186182368
Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye
Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye(ETDRS Letters)Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)Total
Mean50.25 ± 16.2550.71 ± 16.3450.48 ± 16.29
Number of Participants by the BCVA Letter Score Categories in the Study Eye
Number of Participants by the BCVA Letter Score Categories in the Study Eye(Participants)Arm A: Faricimab Q4W (Part 1), Faricimab PTI (Part 2)Arm B: Aflibercept Q4W (Part 1), Faricimab PTI (Part 2)Total
≤34 Letters (20/200 or Worse)7980159
>34 Letters to <55 Letters106105211
≥55 Letters (20/80 or Better)181178359
08

Study locations

194 sites
  • Barnet Dulaney Perkins Eye Center
    Mesa, Arizona 85206, United States
  • Retinal Research Institute, LLC
    Phoenix, Arizona 85014, United States
  • Retina Associates Southwest PC
    Tucson, Arizona 85704, United States
  • Retinal Diagnostic Center
    Campbell, California 95008, United States
  • The Retina Partners
    Encino, California 91436, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835-3424, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • East Bay Retina Consultants
    Oakland, California 94609, United States
  • California Eye Specialists Medical group Inc.
    Pasadena, California 91107, United States
  • Retina Consultants, San Diego
    Poway, California 92064, United States
  • West Coast Retina Medical Group
    San Francisco, California 94109, United States
  • Retina Consultants of Southern Colorado PC
    Colorado Springs, Colorado 80909, United States
  • Colorado Retina Associates, PC
    Lakewood, Colorado 80228, United States
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
  • Advanced Research
    Deerfield Beach, Florida 33064, United States
  • Rand Eye
    Deerfield Beach, Florida 33064, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Fort Lauderdale Eye Institute
    Plantation, Florida 33324, United States
  • Retina Vitreous Assoc of FL
    Saint Petersburg, Florida 33711, United States
  • Retina Associates of Florida, LLC
    Tampa, Florida 33609, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina PC
    Marietta, Georgia 30060-1137, United States
  • Retina Consultants of Hawaii
    'Aiea, Hawaii 96701, United States
  • Northwestern Medical Group/Northwestern University
    Chicago, Illinois 60611, United States
  • Retina Associated Ltd
    Elmhurst, Illinois 60126, United States
  • University Retina and Macula Associates, PC
    Oak Forest, Illinois 60452, United States
  • Prairie Retina Center
    Springfield, Illinois 62704, United States
  • Retina Associates
    Lenexa, Kansas 66215, United States
  • Johns Hopkins Med; Wilmer Eye Inst
    Baltimore, Maryland 21287, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • Cumberland Valley Retina PC
    Hagerstown, Maryland 21740, United States
  • Assoc Retinal Consultants PC
    Royal Oak, Michigan 48073, United States
  • VitreoRetinal Surgery, PLLC.; DBA Retina Consultants of Minnesota
    Edina, Minnesota 55435, United States
  • Midwest Vision Research Foundation
    Chesterfield, Missouri 63017, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Long Is. Vitreoretinal Consult
    Hauppauge, New York 11788, United States
  • Retina Vit Surgeons/Central NY
    Liverpool, New York 13088, United States
  • Retina Assoc of Western NY
    Rochester, New York 14620, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Retina Northwest
    Portland, Oregon 97221, United States
  • Cascade Medical Research Institute LLC
    Springfield, Oregon 97477, United States
  • Mid Atlantic Retina - Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Charleston Neuroscience Institute
    Ladson, South Carolina 29456, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Black Hills Eye Institute
    Rapid City, South Dakota 57701, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Tennessee Retina PC
    Nashville, Tennessee 37203, United States
  • Retina Res Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Retina Associates
    Austin, Texas 78705-1169, United States
  • Austin Clinical Research LLC
    Austin, Texas 78750, United States
  • Retina & Vitreous of Texas
    Bellaire, Texas 77401-3510, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Retina Consultants of Texas
    The Woodlands, Texas 77384-4167, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Retina Associates of Utah, PLLC
    Salt Lake City, Utah 84107, United States
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
  • West Virginia University Eye Institute
    Morgantown, West Virginia 26506, United States
  • Fundacion Zambrano
    Caba, C1017AAO, Argentina
  • Centro Oftalmológico Dr. Charles S.A.
    Capital Federal, C1015ABO, Argentina
  • Oftalmos
    Capital Federal, C1120AAN, Argentina
  • Hospital Italiano; Ophtalmology
    Capital Federal, C1199ABC, Argentina
  • Buenos Aires Mácula
    Ciudad Autonoma Buenos Aires, C1061AAE, Argentina
  • Oftar
    Mendoza, M5500GGK, Argentina
  • Centro Oftalmólogos Especialistas
    Rosario, S2000ANJ, Argentina
  • Grupo Laser Vision
    Rosario, S2000DLA, Argentina
  • Organizacion Medica de Investigacion
    San Nicolás, C1015ABO, Argentina
  • Eyeclinic Albury Wodonga
    Albury, New South Wales 2640, Australia
  • Strathfield Retina Clinic
    Strathfield, New South Wales 2135, Australia
  • Save Sight Institute
    Sydney, New South Wales 2000, Australia
  • Sydney Retina Clinic and Day Surgery
    Sydney, New South Wales 2000, Australia
  • Centre For Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Retina Specialists Victoria
    Rowville, Victoria 3178, Australia
  • The Lions Eye Institute
    Nedlands, Western Australia 6009, Australia
  • LKH-Univ.Klinikum Graz; Universitäts-Augenklinik
    Graz, 8036, Austria
  • Medizinische Universität Wien; Universitätsklinik für Augenheilkunde und Optometrie
    Wien, 1090, Austria
  • Hospital de Olhos de Aparecida - HOA
    Aparecida de Goiania, GO 74980-010, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, RS 90035-903, Brazil
  • Botelho Hospital da Visao
    Blumenau, SC 89052-504, Brazil
  • Universidade Federal de Sao Paulo - UNIFESP*X; Oftalmologia
    Sao Paulo, SP 04023-062, Brazil
  • Hosp de Olhos de Sorocaba
    Sorocaba, SP 18031-060, Brazil
  • Beijing Hospital of Ministry of Health
    Beijing, 100730, China
  • The Second Hospital of Jilin University
    Changchun, 130041, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • Zhongshan Ophthalmic Center, Sun Yat-sen University
    Guangzhou City, 510060, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou City, 310009, China
  • The 2nd Affiliated Hospital of Harbin Medical University
    Harbin, 150001, China
  • Shanghai Tenth People's Hospital
    Shanghai, 200072, China
  • Shanghai First People's Hospital
    Shanghai, 200080, China
  • He Eye Specialist Shenyang Hospital
    Shenyang City, 110034, China
  • The University of Hong Kong-Shenzhen Hospital; Local Ethic Committee
    Shenzhen City, 518053, China
  • Tianjin Eye Hospital
    Tianjin City, 300050, China
  • Tianjin Medical University Eye Hospital
    Tianjin City, 300070, China
  • Eye Hospital, Wenzhou Medical University
    Wenzhou City, 325027, China
  • Renmin Hospital of Wuhan University
    Wuhan, 430060, China
  • Henan Provincial Eye Hosptial
    Zhengzhou, China
  • General Teaching Hospital Prague; Ophthalmology clinic
    Prague, 128 08, Czechia
  • AXON Clinical
    Prague, Czechia
  • Chi De Creteil; Ophtalmologie
    Creteil, 94010, France
  • Hopital Lariboisiere; Ophtalmologie
    Paris, 75010, France
  • Centre Ophtalmologique; Imagerie et laser
    Paris, 75015, France

Showing the first 100 of 194 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2022, 17 months.

Results were first posted in Jan 2024, 1 year 5 months after primary completion. A results delay was requested in Jun 2023.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 17 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2021
First posted
Feb 5, 2021
StartActual
Mar 2, 2021
Primary completionActual
Aug 9, 2022
CompletionActual
Jul 12, 2023
Results delay requested
Jun 2, 2023
Results first posted
Jan 18, 2024
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04740931
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Mar 2, 2021
Primary completion
Aug 9, 2022
Completion
Jul 12, 2023
Results posted
Jan 18, 2024
Last update
Aug 6, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion